Israel - English - Ministry of Health

organon pharma israel ltd., israel - tibolone - tablets - tibolone 2.5 mg - tibolone - tibolone - • complaints resulting from the natural or artificial menopause.treatment of oestrogen deficiency symptoms in postmenopausal women, more than one year after menopause. women above 60 years of age should only start with livial treatment when they are intolerant of, or contraindicated for, other medicinal products approved for the treatment of oestrogen deficiency symptoms.• prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis.for all women the decision to prescribe tibolone livial should be based on an assessment of the individual patient’s overall risks and, particularly in the over 60s, should include consideration of the risk of stroke.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - corifollitropin alfa - solution for injection - corifollitropin alfa 100 mcg / 0.5 ml - corifollitropin alfa - corifollitropin alfa - controlled ovarian stimulation (cos) in combination with a gnrh antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (art) program.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - corifollitropin alfa - solution for injection - corifollitropin alfa 150 mcg / 0.5 ml - corifollitropin alfa - corifollitropin alfa - controlled ovarian stimulation (cos) in combination with a gnrh antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (art) program.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - ganirelix - solution for injection - ganirelix 0.25 mg / 0.5 ml - ganirelix - ganirelix - the prevention of premature luteinsing hormone (lt) surges in women undergoing controlled ovarian hyperstimulation (coh) for assisted reproduction techniques (art).

Israel - English - Ministry of Health

organon pharma israel ltd., israel - betamethasone as dipropionate; betamethasone sodium phosphate - suspension for injection - betamethasone sodium phosphate 2 mg/ml; betamethasone as dipropionate 5 mg/ml - betamethasone - betamethasone - produces anti-inflammatory, anti rheumatic and anti-allergic action and is indicated for systemic and local therapy of acute and chronic corticosteroid-responsive disorders.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - betamethasone acetate; betamethasone sodium phosphate - suspension for injection - betamethasone acetate 3 mg/ml; betamethasone sodium phosphate 3.945 mg/ml - betamethasone - betamethasone - indicated in the management of conditions known to be responsive to corticosteroid therapy.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - betamethasone as dipropionate; gentamicin as sulfate - ointment - betamethasone as dipropionate 0.5 mg / 1 g; gentamicin as sulfate 1 mg / 1 g - topical treatment of dermatosis complicated by secondary infection caused by organisms sensitive to gentamicin

Israel - English - Ministry of Health

organon pharma israel ltd., israel - rizatriptan as benzoate - tablets - rizatriptan as benzoate 10 mg - rizatriptan - rizatriptan - rizalt is indicated for the acute treatment of migraine attacks with or without aura in adults.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - rizatriptan as benzoate - tablets soluble in mouth - rizatriptan as benzoate 10 mg - rizatriptan - rizatriptan - rizalt is indicated for the acute treatment of migraine attacks with or without aura in adults.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - montelukast as sodium - chewable tablets - montelukast as sodium 5 mg - montelukast - montelukast - singulair 5 mg is indicated in adult and pediatric patients 6 years of age and older for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms of the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction. singulair is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. singulair and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. singulair is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older.because the benefits of singulair may not outweigh the risk of neuropsychiatric symptoms in patients with seasonal rhinitis [see warnings and precautions (5.1)], reserve use for patients who have an intolerance to alternative therapies.